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ABSTRACT 
Use of Disulfiram under supervision in well-motivated alcoholics is effective in reducing relapse rates. Several 
adverse effects, some of them life-threatening, have been reported due to the drug. An awareness of the adverse 
effects is useful to keep a follow up and sustain patient compliance with the drug. This study of 158 out patients 
on daily oral disulfiram revealed that though many patients report unpleasant effects most of them could not 
be distinguished from symptoms of alcoholism present before taking disulfiram and hence cannot be considered 
as adverse effects of the drug. The actual adverse symptoms were also mild and could be easily managed 
and were infrequent and not the common cause for poor patient compliance. The study suggests that Disulfiram 
with its low toxicity can be offered to patients without too much reservation. 
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INTRODUCTION 
Alcoholism is a majorgrowing health problem 
all over the world. Disulfiram (DSM) is being used in 
the treatment of alcoholism, since its introduction for 
this purpose in 1948. Use of this drug under super-
vision has been documented to be effective and useful 
even in long-term for well-motivated patients (Ojehagen 
etal 1991). Even if it does not prevent relapses 
completely, it does redue relapse rated and the patients 
arc in sobriety for longer periods than those who are 
not on treatment (Kristensen, 1992). 
Alcoholics often stop taking DSM voluntarily 
for reasons only partly known. Their compliance with 
oral DSM is a troublesome clinical problem. They are 
known to report a high number of adverse effects (AE) 
when treated with DSM (or even placebo) (Christensen 
etal 1984) and it is expected that some of them may 
use the AE as an argument for stopping the drug 
(Brewer et al,1992). Fear about possible AE can 
inhibit the clinician also from continuing therapy. 
Adverse effects of DSM have often been reported in 
the form of case reports. Borup et al (1992) studied 
93 patients on 600 - 800 mgms of DSM twice a 
week for atleast an year and found a low incidence 
of AE. Poulsen etal (1992) have comprehensively 
reviewed the AE featuring in the Adverse Drug 
Reaction reports to the Danish Committee on Adverse 
Drug Relations during the period 1968-1991 and the 
reports to the WHO collaborating centre for Interna-
tional Drug monitoring (numbering 1,131) collected 
Irom a number of national centres around the world. 
They noted occurence of AE at an intermediate fre-
quency of 1 per 200-2000 treatment years. Most 
adverse reactions were of intermediate severity and 
they found no indications that DSM treatment 
imposes a deleterious health impact. Only liver 
damage described as a result of DSM could be life-
threatening, with a mortality rate of about 1:25000pa-
tients per year. Other AE of DSM are not life 
threatening. Poulsen etal (1992) have also noted that 
majority of AE, especially that of liver and peripheral 
nerves are not easily distinguished from manifesta-
tions of alcohol abuse. 
The use of DSM is increasing in India with 
increasing facilities for treatment of alcoholism. It 
would be of benefit to be aware of the profile of AE 
that could be seen in Indian patients to help the 
clinicians in the follow up of the patients. This 
study attempts to answer this issue. It is a cross-
sectional study of patients of alcoholism on outpa-
tients treatment with DSM. The study evaluated only 
the clinically verifiable signs and symptoms and did 
not involve laboratory investigations as a routine. 
The profile of AE reported, their relationship to 
duration of treatment and compliance was studied. 
The doubt whether the adverse symptoms reported 
by patient could be preexisting before starting DSM 
therapy and could be related to prior alcoholism 
rather than the drug was explored. The results are 
presented to highlight the clinical safety of DSM and 
its relevance to treatment of alcoholism. 
MATERIAL AND METHODS: 
Out patients who were under treatment of the 
authors for alcoholism (ICD-10 diagnosis WHO, 1992) 
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was the population from which the study group was 
selected. 158 consecutive patients who had attended 
the clinic for followup and disulfiram therapy in 1994 
formed the study group. All these patients had earlier 
been detoxified as inpatients. They were started on 
DSM only if the level of hepatic enzymes Alanine 
Amino transferase (ALAT) and ASpartate 
aimnotransfera.se (ASAT) in the serum were normal. 
Patients who had other disorders like tuberculosis, 
diabetes mellitus and required concurrent medication 
were not studied. 
The patients were given Tablet Disulfiram (Tor-
rent Laboratories) 250mgms per day every day in a 
week to be taken in the morning with breakfast. The 
drug intake was supervised by wife/parents. Patients 
were reviewed once in 10 days during the first month 
after starting the drug and later at monthly intervals. 
Any symptom which the patient and / or the family 
reported as having developed after starting on DSM 
was noted as an "Adverse Effect" to DSM to begin 
with notwithstanding the subsequent enquiry showing 
that the sympton was present even before taking 
DSM. In addition, a check-list of 36 symptoms 
reported as AE to DSM was made based on descrip-
tions by Poulsen etal (1992) and standard pharmacol-
ogy test books. Eash patient was enquired if he had 
any of the AE on the check list in addition to the 
spontaneously reported ones. As mentioned earlier, 
only the clinical evaluation of AE were done. Labo-
ratory investigations were restricted to estimation of 
serum hepatic enzymes ALAT and ASAT in those 
with gastrointestinal symptoms. 
Following the above enquiry, the relationship 
of onset of AE to starting DSM therapy was queried 
to identify those instances where the symptoms were 
present before taking DSM. The total duration of 
treatment, whether there was discontinuity in the treat-
ment ( a continuous period of more than one week 
without drug was considered as a discontinuation), the 
reasons for such discontinuity and occurence of relapse 
after such discontinuation were also recorded. 
RESULTS: 
All the 158 patients were male and, excepting 
three, were married. All of them were literate with 
atleast primary level education and living within the 
city of Madras and its suburbs. 
65 of the 158 patients reported AE with 30 having a 
single AE and others having 2 or more symptoms, 
totalling 137 instances of AE. When comparing 
patiens on continuous and discontinuous treatment 
neary equal proportion of them i.e. 28 out of 75 and 
37 out of 83 respectively, reported adverse effects. 
But the number of symptoms experienced were more 
in those on regular treatment (totalling 84 symptoms, 
averaging 3 per patient) which is twice that reported 
by those taking discontinuous treatment (53 symp-
toms averaging 1.4 per patient). Overall the common-
est symptoms were (number of patients in parenthe-
ses) tiredness (31), Gastrointestinal including anorex-
ia, nauaea, vomiting, abdominal pain, bloating of stom-
ach, constipation, diarrhoea and jaundice (23), periph-
eral neuritis (13) and non-psychotic psychiatric symp-
toms like anxiety, depression (12). Other common AE 
were drowsiness (9), sleep disturbance (7). Psychosis 
(7) and confusion (4). Infrequently reported symp-
toms were dizziness, headache and tremors (2 each) 
and one case of irritability, ideas of reference, redued 
libido, loss of visual acuity, irritation in the eyes and 
odd taste in the mouth. Liver enzymes in the 23 
patients with gastrointestinal symptoms were normal. 
50 of the 65 patients experienced some or all of the 
'AE' before starting to take DSM accounting for 85 
out of 137 instances of AE. Hence only these 85 
instances could be considered as actual adverse effect 
of DSM. The proportion of patients having the 
symptoms in the pre-DSM period also were as fol-
lows: Tiredness (20/31), Gastrointestinal symptoms 
(20/23), peripheral neuritis (7/13), anxiety/depression 
(6/12) drowsiness (3/9), psychosis (7/7) sleep distur-
bance (5/7) and confusion (2/4). Of the remaining 
symptoms loss of libido, odd taste in the mouth and 
irritation in the eyes were experienced only after 
taking DSM. Hence only the symptom of drowsi-
ness, with least doubt, occured more often after taking 
disulfiram. 
On examining the relationship of duration of treatment 
to AE, irrespective of whether there were periods of 
non-compliance, no association was discovered. 35 of 
80 patients on less than 6 months of treatment and 
30 of 78 patients on more than 6 months of treatment 
reported AE. This lack of difference persisted when 
the groups were subdivided into those receiving treat-
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ment for one month or less, 1 to 3 months and 4 to 
36 months. To make the observation more meaningful 
only those patients on continuous treatment were 
analysed (N-83, totalling 621 months of treatment). 
There was no difference in frequency of AE in patients 
of either groups (28 of 59 on less than 6 months 
treatment and 9 of 24 on longer treatment had AE). 
The time of onset of the frequently occuring symp-
toms were looked into. The symptoms of 
gastrointestinal tract (15 to 23), anxiety/depression (8 
of 12) and drowsiness (8 to 9) occured more often in 
those on less than 6 months treatment. (The same 
trend was 
seen in patients on less than 3 months treat-
ment) 6 of 7 cases of psychosis occured after 6 
months of treatment. Symptoms like tiredness (15 of 
31), peripheral neuritis (7 of 13), sleep disturbance (4 
of 7) and confusion (2 of 4) occured equally in both 
treatment- duration groups. 
The reasons of discontinuation of treatment 
were analysed. 75 of the 158 patients had discontin-
ued taking DSM at least once. Only 6 of them gave 
the 'AE' of DSM as the reason for stopping the drug. 
Others often stopped the drug because they felt that 
they could manage without the drug or wanted to drink 
again. 52 of the 75 experienced a relapse into alcohol 
abuse on stopping the drug but all of them were 
willing to continue the treatment subsequently. 
DISCUSSION: 
The study suggests, on initial analysis that 
alcoholics frequendy experience adverse effects due to 
disulfiram. But further examination of the time of 
onset of symptoms revealed that majority of them 
were present before taking the drug and hence cannot 
be considered as an adverse effect of DSM. The 
reason for such fallacious reporting could be that under 
the influence of alcohol the symptoms were either not 
troublesome or ignored but were brought to focus 
during sobriety with disulfiram. It is also possible that 
in some cases the symptoms could have become more 
severe due to DSM. Only the symptoms of drowsi-
ness and that too in a small number was reported more 
often after starting the drug. All the actual AE were 
mild in nature and did not require any vigorous treat-
ment or discontinuation of disulfiram. No instances of 
hepatic dysfunction was seen, probably because of 
careful selection of DSM of cases before starting 
DSM. Anyway, no longterm illeffects of DSM on 
liver have been reported (Borup etal, 1992). 
The adverse symptoms that occured early in 
the treatment with DSM were the gastrointestinal 
ones, anxiety/ depression and drowsiness. As already 
noted only drowsiness could be related with any 
confidence to DSM rather than predrug alcoholism. 
The frequency of drowsiness decreased with continued 
treatment indicating that it is a short-term AE of the 
drug. The complaint was managed by administering 
the drug at bed time instead of in the morning. 
A latency in the time of onset of AE to DSM 
was reported for different organ systems (Poulsen etal 
1994) . Skin Reactions peak after 2 weeks, hepatitis 
at 2 months and neurological symptoms increase with 
duration of therapy. In this study, to begin with, no 
skin or hepatic AE were noted. The neurological 
symptoms of peripheral neuritis and confusion was 
equally prevalent irrespective of duration of treatment. 
Psychosis in almost all the cases emerged in those 
patients on long duration of treatment. As all these 
patients had psychosis before the Disulfiram treat-
ment it could possily indicate an aggravating effect of 
the drug, if it is not a relapse of the illness in its 
natural course. Disulfiram was continued in these 
patients alongwith antipsychotic measures as they 
were able to understand the risk of ingesting alcohol 
while taking DSM. 
Adverse effects of a drug could understandably 
cause poor patient compliance. So it was interesting 
to note in our study that though 75 out of 158 
patients had discontinued treatment at least once, 
only 6 of them blamed the adverse effects of DSM for 
their non-compliance. Moreover it was seen that 
patients on regular treatment had more number of 
adverse symptoms thereby showing that AE of the 
drug had no relation to poor drug compliance. This 
observation is similar to that of Liskow et at (1990) 
who found that only 20% of their 345 patients gave. 
As reason for stopping DSM and none of the 
210 patients who discontinued DSM under treatment 
by Borup et al (1992) blamed the AE of the drug. 
This suggests that the AE of DSM are not too 
disturbing especially when weighed against the risks of 
relapse of alcoholism. Proper reassurance and manage-
ment would help patients maintain treatment compli-
ance. 
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The study indicated that the AE of Disulfiram 
are infrequent and mild. The frequent attribution of 
symptoms existing even before taking the drug to the 
drug confounds evaluation of adverse effects to 
Disulfiram. This has to be taken into account in 
studying the adverse effects of the drug. Most 
importantly AE are found not to contribute to poor 
compliance. Hence, as Brewer etal (1992) pointed 
out, with this relative low toxicity of the drug espe-
cially compared with toxicity of alcohol, Disulfiram 
could be safely offered to a wide range of patients 
with alcohol problems rather than being thought of as 
a last resort 
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